Ranibizumab

【Product name】Lucentis

[English common name]Ranibizumab

[Chinese common name]Ranibizumab

[English name]

[Chinese other name]

[Indications] LUCENTIS is indicated for the treatment of the following patients:
(1) Neovascular (wet) age-related macular degeneration (AMD)
(2) macular edema after retinal vascular occlusion (RVO)
(3) Diabetic macular edema (DME)

[Usage and Dosage] Only for intraocular injection of ophthalmology.
Neovascular (wet) age-related macular degeneration (AMD)
LUCENTIS 0.5 mg (0.05 mL) is recommended for intravitreal injection once a month (approximately 28 days).
Although not as effective, the patient can be treated with three monthly doses followed by a lower frequency dose and a regular assessment. At 9 months after 3 initial monthly doses, a lower frequency administration with an average of 4-5 doses is expected to maintain vision and a monthly dose may be expected to result in an average increase of 1-2 letters. Patients should be assessed regularly.
Although not as effective, patients can receive 1 dose every 3 months after 4 monthly doses. Administration every 3 months for the next 9 months would result in an average of about 5-letter (1-line) loss of vision loss compared to continuing monthly dosing. Patients should be assessed regularly.
Macular edema after retinal vascular occlusion (RVO) (2.3)
(1) Intravitreal injection is recommended once a month (about 28 days) for administration of LUCENTIS 0.5 mg (0.05 mL). In the RVO clinical study, patients received LUCENTIS injections for 6 months each month. Despite the optical coherence tomography and vision re-treatment criteria, the experienced patients then did not receive treatment on average 6 months, while the patients lost vision at 7 months without treatment at 7 months. Patients should be treated every month.
Diabetic macular edema (DME)
(1) Intravitreal injection is recommended for administration once a month (about 28 days) of LUCENTIS 0.3 mg (0.05 mL).
Dosage form and specification
(1) 10 mg/mL solution (LUCENTIS 0.5 mg)
(2) 6mg/mL solution (LUCENTIS 0.3mg)

[Storage] 2~8°C protected from light and should not be frozen. Please store in a place that is not accessible to children.

[Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.